Herceptin Plus Taxol Reduces Recurrence Risk of Small HER2-Positive Breast Cancers
Results from an early study suggest that a combination of Herceptin and Taxol reduce the risk of recurrence of small HER2-positive breast cancers that haven't spread to the lymph nodes.
A small study suggests that a combination of the targeted therapy Herceptin (chemical name: trastuzumab) and the chemotherapy medicine Taxol (chemical name: paclitaxel) given after surgery reduced the risk of recurrence (the cancer coming back) of small HER2-positive breast cancers that haven’t spread to the lymph nodes.
The study was published in the Jan. 8, 2015 issue of the New England Journal of Medicine. Read the abstract of “Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer.”
HER2-positive cancers have too many copies of the HER2/neu gene, which make too much of the HER2 protein. The HER2 protein sits on the surface of cancer cells and receives signals that encourage the cancer to grow and spread. About one out of every four breast cancers is HER2-positive.
Herceptin works by attaching to the HER2 protein and blocking it from receiving growth signals. Herceptin, which is given intravenously, is approved by the U.S. Food and Drug Administration (FDA) to:
- treat advanced-stage HER2-positive breast cancers
- lower the risk of recurrence of early-stage HER2-positive breast cancers with a high risk of recurrence
A newer form of Herceptin, Herceptin Hylecta (chemical name: trastuzumab and hyaluronidase-oysk), can be given as an injection.
Taxol, a taxane chemotherapy, works by interfering with the ability of cancer cells to divide. Taxol usually is given in combination with other medicines and is used after surgery to:
- reduce the risk of early-stage breast cancer coming back
- treat advanced-stage breast cancer after it stops responding to standard chemotherapy regimens that include an anthracycline
Taxol is given intravenously.
Treatments given after surgery to reduce the risk of recurrence are called adjuvant treatments.
While Herceptin and chemotherapy are commonly used to treat larger HER2-positive breast cancers that have a high risk of recurrence, there is no current standard treatment for small HER2-positive breast cancers with a low risk of recurrence. Some of these small cancers aren’t treated with Herceptin at all and others are treated with Herceptin and several other chemotherapy medicines.
"Women with small, HER2-positive, node-negative breast tumors have a low, but still significant, risk of recurrence of their disease," said Eric Winer, M.D., director of the Breast Oncology Program at the Susan F. Smith Center for Women's Cancers at Dana-Farber and senior author of the study. Dr. Winer also is a member of the Breastcancer.org Professional Advisory Board. "This study demonstrates that a combination of lower-intensity chemotherapy and trastuzumab -- which is associated with fewer side effects than traditional chemotherapy regimens -- is an appealing standard of care for this group of patients."
In the study, the researchers wanted to know if a combination of Herceptin and just one chemotherapy medicine, Taxol, would offer benefits to women diagnosed with small HER2-positive breast cancers that hadn’t spread to the lymph nodes and had a low risk of recurrence. This combination is a more aggressive treatment than not using Herceptin, but less aggressive than using Herceptin and more than one chemotherapy medicine.
About 400 women diagnosed with HER2-positive breast cancer were in the study. All the cancers were smaller than 3 cm and none of the cancers had spread to the lymph nodes.
The women received Taxol and Herceptin for 12 weeks, followed by 9 months of Herceptin alone. The researchers wanted to know how long the women lived without the cancer coming back (disease-free survival).
After about 3 years of follow-up, 98.7% of the women were alive and hadn’t had the cancer come back. This means that only 1.3% of the women had the cancer come back.
Herceptin can cause heart problems, including decreased heart function and heart failure. In this study, only 0.5% (2 women) had congestive heart failure and these problems went away after the women finished Herceptin. About 3% of the women had decreased heart function while being treated with Herceptin, but 11 of the women were able to start treatment again after taking a short break. About 3% of the women (13 women) had neuropathy.
The study suggests that women with small, HER2-positive breast cancers that haven’t spread to the lymph nodes can be treated with Herceptin and a chemotherapy regimen that’s less aggressive than doctors previously thought and still have the same excellent chances of making a full recovery and being cancer-free.
If you’ve been diagnosed with HER2-positive breast cancer that is smaller than 3 cm and hasn’t spread to the lymph nodes, you and your doctor will consider the characteristics of the cancer, your unique situation, any other health issues you have, and your personal preferences when creating your treatment plan. Ask your doctor why Herceptin is or isn’t recommended for you after surgery and how that decision was made. You also may want to talk to your doctor about this study.
Using the most complete and accurate information possible, you and your doctor can develop a treatment plan that makes the most sense for you. And stay tuned to Breastcancer.org for the latest information on the standard of care for small HER2-positive breast cancers.
Editor’s Note: This article was updated with information about Herceptin Hylecta, which the FDA approved on Feb. 28, 2019.
— Last updated on July 31, 2022, 10:24 PM
Share your feedback
Help us learn how we can improve our research news coverage.
Was this article helpful?